Sign in

TLX on Nasdaq

TELIX PHARMACEUTICALS LIMITED

Logo: telixpharma.com3

TELIX PHARMACEUTICALS LIMITED is an Australian public company.1 Its shares trade on Nasdaq under the symbol TLX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$803.8MRevenue, fiscal 20254
-$7.1MNet income, fiscal 20254

Compare with COLLEGIUM PHARMACEUTICAL, INC, Arrowhead Pharmaceuticals or Corcept Therapeutics, or pick any stock.

  • TickerTLX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersC31
  • Websitetelixpharma.com
  • Incorporated inAustralia5
  • Business address55 Flemington Road, North Melbourne, C3 30515
  • Filer categoryLarge accelerated filer5

See how the biggest companies compare on our leaderboards

TELIX PHARMACEUTICALS LIMITED image from its website
Image: telixpharma.com3

Analysis and Retrieval system, which may be accessed through the SEC’s website at www.sec.gov.6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

53.1%Gross margin4
3.7%Operating margin4
-0.9%Net margin4
55.6%Revenue growth, 20254
-1.7%Return on equity4
0.94×Debt to equity4
-$43.0MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue47¢$377.4M
  • Research and development21¢$171.2M
  • Other costs31¢$253.1M
  • Interest0¢$181.0K
  • Income tax0¢$1.9M

Out of $803.8M in revenue.4 The company lost money this year.

Financial statements

Revenue4$803.8M in 2025+141% since 2023
0$250.0M$500.0M$750.0M$1.0B2023: $333.0M$333.0M20232024: $516.6M$516.6M2024+55%2025: $803.8M$803.8M2025+56%
Gross profit4$426.4M in 2025+104% since 2023
0$200.0M$400.0M$600.0M2023: $209.5M$209.5M20232024: $336.2M$336.2M2024+60%2025: $426.4M$426.4M2025+27%
Operating income4$29.8M in 2025+170% since 2023
0$20.0M$40.0M$60.0M2023: $11.0M$11.0M20232024: $55.2M$55.2M2024+401%2025: $29.8M$29.8M2025−46%
Net income4-$7.1M in 2025
-$20.0M0$20.0M$40.0M2023: $4.2M$4.2M20232024: $33.7M$33.7M2024+700%2025: -$7.1M-$7.1M2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Revenue from contracts with customers$803.8M$516.6M$333.0M
Cost of sales-$377.4M-$180.4M-$123.4M
Gross profit$426.4M$336.2M$209.5M
Research and development costs-$171.2M-$127.9M-$85.3M
Selling and marketing expenses-$96.8M-$56.0M-$33.5M
Manufacturing and distribution costs-$44.6M-$16.7M-$6.3M
General and administration costs-$95.8M-$85.3M-$49.7M
Other gains/(losses)(net)$11.7M$4.9M-$23.8M
Operating profit$29.8M$55.2M$11.0M
Finance income$5.8M$7.2M$671.0K
Finance costs-$40.9M-$24.4M-$9.1M
(Loss)/profit before income tax-$5.3M$37.9M$2.6M
Income tax (expense)/benefit-$1.9M-$4.2M$1.6M
(Loss)/profit for the year-$7.1M$33.7M$4.2M
Owners of Telix Pharmaceuticals Limited-$7.1M$33.7M$4.2M
Changes in the fair value of investments at fair value through other comprehensive income-$1.2M-$3.3M-$612.0K
Exchange differences on translation of foreign operations-$5.8M$5.6M-$1.9M
Total comprehensive (loss)/income for the year-$14.1M$36.0M$1.7M
Owners of Telix Pharmaceuticals Limited-$14.1M$36.0M$1.7M
Basic (loss)/earnings per share from continuing operations after income tax attributable to the ordinary equity holders of the Company (in dollars per share)-$0.02$0.10$0.01
Diluted (loss)/earnings per share from continuing operations attributable to the ordinary equity holders of the Company (in dollars per share)-$0.02$0.10$0.01

Compare TELIX PHARMACEUTICALS LIMITED with another company

Corporate structure

TELIX PHARMACEUTICALS LIMITED sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of TELIX PHARMACEUTICALS LIMITED

  • Andreas Kluge Filed SCHEDULE 13G on TELIX PHARMACEUTICALS LIMITED, latest Feb 14, 2025
  • Christian Behrenbruch Filed SCHEDULE 13G on TELIX PHARMACEUTICALS LIMITED, latest Feb 14, 2025
  • TELIX PHARMACEUTICALS LIMITED C3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What TELIX PHARMACEUTICALS LIMITED reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$58.7M4 Dec 31, 2025$27.8M4 Dec 31, 2024+110.7%
Operating-lease assets (leased space)$57.0M4 Dec 31, 2025$5.8M4 Dec 31, 2024+881.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$141.9M4 Dec 31, 2025$440.0M4 Dec 31, 2024−67.8%
Long-term investments$37.1M4 Dec 31, 2025$34.7M4 Dec 31, 2024+6.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$199.0M4 Dec 31, 2025$66.6M4 Dec 31, 2024+198.8%
Intangible assets, net (excluding goodwill)$592.8M4 Dec 31, 2025$257.9M4 Dec 31, 2024+129.9%

Inventory

ItemLatestA year beforeChange
Inventory, total$37.1M4 Dec 31, 2025$23.6M4 Dec 31, 2024+57.0%
Raw materials$18.7M4 Dec 31, 2025$8.9M4 Dec 31, 2024+110.1%

Leadership

Who has led TELIX PHARMACEUTICALS LIMITED, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Christian Behrenbruch2026–now

Chief financial officer

  1. Darren Charlton Smith2026–now

Chief operating officer

  1. Darren Joel Patti2026–now
Board members and other officers (7)

Timeline

  1. Mar 18, 2026New chief executive Christian Behrenbruch becomes CEO7
  2. Nov 15, 2017Went public Listed on Australian Securities Exchange1

Calendar

Drug trials and FDA: coming up

  1. Jan 2027Phase 3 trial readout expected Phase 3 trial of 68Ga-PSMA-11 in PCA: primary completion expected Jan 2027 (ClinicalTrials.gov NCT07052214).16
  2. Jul 2027Phase 3 trial readout expected Phase 3 trial of TLX-101-Tx + Lomustine in Neoplastic Disease: primary completion expected Jul 2027 (ClinicalTrials.gov NCT07100730).17
  3. Aug 31, 2027Phase 3 trial readout expected Phase 3 trial in ccRCC: primary completion expected Aug 31, 2027 (ClinicalTrials.gov NCT07197580).18

Drug trials and FDA: recently

  1. Sep 11, 2026FDA approval FDA approved Pixclara (floretyrosine f-18), a new molecular entity, priority review, orphan drug (NDA 218592).19

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

104 filings to the SEC since October 2021: 3 annual reports, 13 insider forms, 2 large holders, 86 other. The latest 20:

  1. Sep 30, 20266-K EDGAR
  2. Sep 21, 20266-K EDGAR
  3. Sep 14, 20264 EDGAR
  4. Sep 14, 20266-K EDGAR
  5. Sep 2, 20266-K EDGAR
  6. Sep 1, 20266-K EDGAR
  7. Aug 20, 20266-K EDGAR
  8. Jul 21, 20266-K EDGAR
  9. Jul 2, 20266-K EDGAR
  10. May 21, 20266-K CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS EDGAR
  11. May 18, 20263 EDGAR
  12. May 18, 20263 EDGAR
  13. May 18, 20263 EDGAR
  14. May 6, 20264 EDGAR
  15. Apr 23, 20266-K CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS EDGAR
  16. Apr 21, 20266-K CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS EDGAR
  17. Apr 20, 20266-K CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS EDGAR
  18. Apr 14, 20266-K EDGAR
  19. Apr 14, 20266-K EDGAR
  20. Apr 13, 20266-K CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS EDGAR

The 104 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 7, 2026Smith Darren CharltonGroup Chief Financial OfficerBuy2,071$9.66$20.0KForm 4
Apr 29, 2026Behrenbruch ChristianMD & Group CEOBuy33,435$14.87$497.2KForm 4
Apr 28, 2026Behrenbruch ChristianMD & Group CEOBuy34,500$14.48$499.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 62. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC561,206$6.5M0.0%−3,551
Lazard Asset Management LLC284,207$3.3M0.0%−5,710
Portland Investment Counsel Inc.266,200$3.1M0.9%No change
Private Advisor Group, LLC197,250$2.3M0.0%+22,835
Marshall Wace, Llp189,188$2.2M0.0%New
Morgan Stanley165,978$1.9M0.0%+49,538
Integrated Wealth Concepts LLC164,397$1.9M0.0%No change
Hennion & Walsh Asset Management, Inc.150,138$1.7M0.0%New
UBS Group AG134,698$1.6M0.0%+102,398
Blair William & Co/il122,985$1.4M0.0%New
Raiffeisen Bank International AG115,000$1.3M0.0%−15,000
Quadrature Capital Ltd102,425$1.2M0.0%New
Jpmorgan Chase & Co77,538$876.2K0.0%+20,190
XY Capital Ltd71,291$822.0K0.9%+58,739
XTX Topco Ltd68,776$793.0K0.0%+42,769
Vanguard Personalized Indexing Management, LLC58,989$680.1K0.0%+25,736
NLB Skladi, upravljanje premozenja, d.o.o.58,000$668.7K0.0%New
Mariner, LLC37,085$427.6K0.0%−6,361
Capricorn Fund Managers Ltd36,100$416.2K0.0%New
Gts Securities LLC35,537$409.7K0.0%New
Jane Street Group, LLC33,389$385.0K0.0%New
IHT Wealth Management, LLC32,295$372.4K0.0%+7,260
SummitTX Capital, L.P.31,621$364.6K0.0%New
Portolan Capital Management, LLC25,424$293.1K0.0%−515,843
Bnp Paribas Financial Markets20,516$236.5K0.0%+8,516

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How TELIX PHARMACEUTICALS LIMITED is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTelix Pharmaceuticals Ltd2
  • CIK0002007191
  • Filer statusLarge accelerated filer not an emerging growth company; not a shell company6
  • Incorporated inAustralia6
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address55 Flemington Road, North Melbourne, C3 30512
  • Phone61 3 9093 38552
  • Shares outstanding338,777,049 shares as of Dec 31, 20256
  • AuditorPricewaterhouseCoopers, Melbourne, Australia PCAOB ID 1379; it also attests to the company’s internal control over financial reporting6
  • On EDGAR sinceJan 25, 20242
  • Filings104 in all: 6-K (61), 3 (10), DRS/A (4), 4 (3), 20-F (2), CORRESP (2), DRS (2), F-6 (2)2
    All 23 form types

    RW (2), SCHEDULE 13G (2), SEC STAFF LETTER (2), 20-F/A (1), 20FR12B (1), 20FR12B/A (1), 8-A12B (1), CERT (1), EFFECT (1), F-1 (1), F-1/A (1), F-3ASR (1), S-8 (1), SEC STAFF ACTION (1), UPLOAD (1)

  • Latest filingsAnnual report (20-F) Feb 20, 2026

Securities registered for trading

ClassSymbolExchange
American depositary sharesTLXThe Nasdaq Global Select Market

From the cover page of the 20-F filed Feb 20, 2026 (Section 12(b) of the Exchange Act).6

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21